Novo Nordisk's semaglutide beats its counterpart liraglutide to become the next generation of weight loss innovation, and then Eli Lilly's GLP-1R/GIPR dual-target agonist tirzepatide achieves a 22.5% weight loss, surpassing semaglutide's weight loss history
For patients trying to find the most cost-effective approach, our peptide cost calculator can help compare expenses across different treatment options and timeframes
PMCID: PMC7992610 ) Zhu CS, Kwan EA, Williams GM, Lewin-Smith M, Lincoln MS, Lee AJ (2022) Exenatide-induced granulomatous panniculitis associated with poly(d, l-lactide-co-glycolide)
Holly Lofton, a doctor who specializes in obesity medicine at NYU Langone Health in New York
However, online forums sometimes label retatrutide a "GLP-3." This is inaccurate no "GLP-3" receptor exists